C-XHURiPSC-thymic cells, machine learning, cell therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Develop therapies for immune decline associated with aging.
Therapeutic application of Thymmune's iPSC-thymic cell manufacturing and thymic cell engineering platform.
Listed as a target therapeutic area; no specific candidate, study, or clinical milestone disclosed in the supplied material.
Develop therapies for autoimmune disorders by restoring normal immune function.
Therapeutic application of Thymmune's iPSC-thymic cell manufacturing and thymic cell engineering platform.
Listed as a target therapeutic area; no specific candidate, study, or clinical milestone disclosed in the supplied material.
Develop therapies for immunodeficiencies by restoring immune function.
Therapeutic application of Thymmune's iPSC-thymic cell manufacturing and thymic cell engineering platform.
Listed as a target therapeutic area; no specific candidate, study, or clinical milestone disclosed in the supplied material.
Restore normal immune function in aging and disease by generating thymic cells for therapeutic use.
Machine learning-driven iPSC-thymic cell engineering and manufacturing approach intended to generate off-the-shelf cells at scale.
Received $37M in ARPA-H funding in 2023 to support the platform/company program; previously raised $7M seed financing in 2022.
Develop therapies for transplant-related disorders by restoring or normalizing immune function.
Therapeutic application of Thymmune's iPSC-thymic cell manufacturing and thymic cell engineering platform.
Listed as a target therapeutic area; no specific candidate, study, or clinical milestone disclosed in the supplied material.